On Tuesday, Shares of Rambus Inc. (NASDAQ:RMBS), gained 1.25% to $11.37.
S&P SmallCap 600 constituent Standard Pacific Corp. (SPF) will replace Helix Energy Solutions Group Inc. (HLX) in the S&P MidCap 400, Helix will replace Standard Pacific in the S&P SmallCap 600, and Rambus Inc. (RMBS) will replace Ryland Group Inc. (RYL) in the S&P SmallCap 600 after the close of trading on Thursday, October 1. Standard Pacific, which is changing its name to CalAtlantic Group, is acquiring Ryland Group in a deal predictable to be accomplished on or about that date, pending final approvals. Helix has a market capitalization more representative of the small-cap market space.
Standard Pacific operates as a builder of single-family attached and detached homes. Headquartered in Irvine, CA, the company will be added to the S&P MidCap 400 GICS (Global Industry Classification Standard) Homebuilding Sub-Industry index.
Helix Energy Solutions provides specialty services to the offshore energy industry. Headquartered in Houston, TX, the company will be added to the S&P SmallCap 600 GICS Oil & Gas Equipment & Services Sub-Industry index.
Rambus operates as a technology solutions company. Headquartered in Sunnyvale, CA, the company will be added to the S&P SmallCap 600 GICS Semiconductors Sub-Industry index.
Rambus Inc. operates as a technology solutions company in South Korea, the United States, Japan, Europe, Canada, Asia, and internationally. The company’s technology solutions comprise memory, chip interfaces and architectures, end-to-end security, and advanced LED lighting.
Shares of Neuralstem, Inc. (NASDAQ:CUR), declined -12.66% to $1.38, during its last trading session.
Neuralstem, Inc. (CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, declared that nine-month Phase II and combined Phase I and Phase II data on the NSI-566 trial in amyotrophic lateral sclerosis (ALS) was presented at the American Neurological Association Annual Meeting by principal investigator, Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health. The data showed that the intraspinal transplantation of the cells was safe and well-tolerated throughout the escalating doses, reaching a maximum tolerated dose of 16 million cells via 20 bilateral injections. There appeared to be no acceleration in disease progression due to the therapeutic intervention.
Researchers calculated a 95% confidence limit around the slopes of decline of ALSFRSr scores, forced vital capacity (FVC) and grip strength of the ProAct historical database subjects, and evaluated if trial subjects fell within or outside those limits. 73% of Phase II patients, and 79% of combined Phase I and II patients, fell above the upper confidence limit of the ALSFRSr score. 50% of Phase I and II combined, and 40% of Phase II patients’ forced vital capacity percent predicted fell above the upper confidence limit, contrast to the ProAct database. ALSFRSr scores correlated most strongly with FVC preservation, which was the target of the cervical injections. For grip strength control, researchers used the Ceftriaxone (CEF) study database, since grip strength data was not accessible in the ProAct database. 67% of Phase I and II combined, and 60% of Phase II patients, all at nine months post-intervention, fell above the 95% upper confidence limit.
Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds.
Shares of Viavi Solutions Inc (NASDAQ:VIAV), declined -0.37% to $5.34, during its last trading session.
Viavi Solutions (NASDAQ: VIAV) declared that it will highlight its latest solutions that enable and accelerate quality optical communications netoperates and services during the 41stEuropean Conference on Optical Communications (ECOC) at Fiera Valencia in Valencia, Spain, Sept. 27 - Oct. 1, booth #100.
Viavi assists global customers, counting those serving the fiber optic industry at ECOC, to profitably scale, meet demands of exploding applications, connected devices and video, and transition to virtualized, software-based netoperates, 100G and more.
Viavi Solutions Inc. engages in the network enablement, service enablement, and communications and commercial optical products businesses. The company’s Network Enablement segment provides an integrated portfolio of testing solutions that access the network to perform build out and maintenance tasks. This segment’s solutions comprise instruments, software, and services to design, build, turn-up, certify, troubleshoot, and optimize netoperates.
Finally, Stratasys, Ltd. (NASDAQ:SSYS), ended its last trade with -9.26% loss, and closed at $26.17.
Stratasys Korea, partner of Stratasys, Ltd. (SSYS), a global leader of 3D printing and additive manufacturing solutions, introduces the Objet30 Dental Prime, a high quality, low cost 3D printer designed to allow smaller dental labs to produce a wide range of models and appliances in-house.
While compact in size, the Objet30 Dental Prime is big in versatility, starting with a choice of 3D print modes: High Quality and High Speed. The High Quality mode 3D prints models with superior surface finish and intricate, delicate features required for precise fittings on crown, bridge, and prosthetic models (in 16-micron layers). The High Speed mode 3D prints at accelerated speeds to produce orthodontic models and surgical guides with raised productivity (in 28 micron layers). Together, these two print modes enable smaller labs to produce a wide range of dental and orthodontic appliances in-house — changing the economies for smaller dental labs by increasing productivity, shortening delivery times and improving patient satisfaction.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
